Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.17−0.04 (-0.12%)
Close on Nov 18, 2026Market cap $6.85BP/E –Yield –
Immunovant net income
Net income is the profit left for shareholders after every expense, interest and tax.
Immunovant's net income for the twelve months ending Jun 30, 2026 was -$538.22M. For fiscal 2026 it was -$505.61M. The highest annual figure on record is -$28.60M in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$505.61M | – |
| FY2025 | Mar 31, 2025 | -$413.84M | – |
| FY2024 | Mar 31, 2024 | -$259.34M | – |
| FY2023 | Mar 31, 2023 | -$210.96M | – |
| FY2022 | Mar 31, 2022 | -$156.73M | – |
| FY2021 | Mar 31, 2021 | -$107.43M | – |
| FY2020 | Mar 31, 2020 | -$66.39M | – |
| FY2019 | Mar 31, 2019 | -$28.60M | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$153.22M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$147.86M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$110.64M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$126.50M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$120.61M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$106.45M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$111.12M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$109.12M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$87.15M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$75.32M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$51.42M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$58.66M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$73.94M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$59.43M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$63.23M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$47.93M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$40.37M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$47.17M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$41.39M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$37.70M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$30.47M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$28.16M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$31.78M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$20.79M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$26.71M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$31.85M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$20.06M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$450 | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$8.85M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$6.35M | – |
| Q1 FY2019CQ2 2018 | Jul 6, 2018 | -$4.37M | – |
See a number that looks wrong?